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Abstract 
Daptomycin (Dap) is a Ca2+-dependent cyclic lipodepsipeptide antibiotic used for 
treating skin infections caused by Gram-positive pathogens. It is also used to treat endocarditis 
caused by Staphylococcus aureus including methicillin-resistant S. aureus (MRSA). The 
mechanism of action (MOA) for Dap is still somewhat unclear. Thus, the MOA for Dap has 
been a focus of considerable study, and many MOAs have been proposed. Nevertheless, a 
considerable amount of evidence has been amassed that suggests Dap binds to bacterial cell 
membranes and forms oligomeric pores that allow for the passage of small cations. This results 
in the depolarization of the cell membrane and cell death. The first goal of this study was to 
identify the contribution of each amino acid in Dap to its biological activity and membrane 
affinity. This was achieved by performing an alanine scan on an active Dap analog, Dap-E12-
W13, whereby each residue was replaced with alanine through chemical synthesis.  The 
antibacterial activity of the alanine analogs was determined against Bacillus subtilis.  These 
studies revealed that positions 2, 6, and 11 are amenable to substitution. These studies, in 
conjunction with those performed earlier on Dap, also suggested that position 8 is amenable to 
substitution as long as the correct stereochemistry is maintained.  Membrane binding studies 
using model liposomes revealed that the position 2, 6 and 11 analogs were able to interact with 
membranes in a manner very similar to that of the parent peptide Dap-E12-W13, in that they 
did not require high concentrations of calcium to achieve maximal membrane binding.  This 
was in contrast to the other Ala mutants which required much greater than physiological Ca2+ 
ion concentrations to achieve maximal interactions and good biological activity.   
The second goal of this study was to create one or more Dap analogs that have activity 
equal to or greater than that of Dap, with the long-term goal of creating a Dap analog that is 
active against resistant bacterial strains and in the presence of lung surfactant. Towards this 
end, Ser11 of an active Dap analog, Dap-K6-E12-W13, was substituted with 17 common amino 
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acids. Although none of the resulting analogs were more active than Dap, these studies revealed 
that position 11 was amenable to substitution with positively charged amino acids (His, Arg, 
Lys) as these substitutions resulted in either no or minimal loss of activity.  Moreover, the Asn, 
Thr, Cys, Met and Gly analogs were also relatively active being only 2.7-fold less active than 
Dap-K6-E12-W13 at 1.25 mM Ca2+.   
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Chapter 1 
Daptomycin 
1.1 Antibiotics 
Throughout much of human history the number one cause of death to humankind 
was bacterial infections.1 Fortunately, many infections that used to be fatal can now be 
treated with antibiotics. The discovery and development of antibiotics have been credited 
as the reasons for the increase in the human lifespan over the last century.1  Consequently, 
it is safe to say that one of the most important advances ever made in medical science was 
the discovery and development of anti-bacterial drugs. 
It was not until the late 19th century that scientists began to scientifically search for 
and study antibacterial chemicals.1 One of the first scientists to do so was the German 
physician Paul Ehrlich. He found that certain chemical dyes often colour some bacterial 
cells but not others.2,3 Among his accomplishments was the discovery that certain dyes 
could be used as drugs which would kill a specific organism while leaving other tissues 
unharmed.4 Suggesting that it is possible to create substances or compounds that can kill 
certain bacteria selectively without harming other cells.2,3 In 1909, he discovered that a 
chemical called arsphenamine or Salvarsan was an effective treatment for syphilis. This 
became the first modern anti-bacterial drug.5,6 Ehrlich referred to his discovery as 
'chemotherapy' – the use of a chemical to treat a disease.  The word “antibiotics” was first 
used over 30 years later by the Ukrainian-American inventor and microbiologist Selman 
Waksman, who in his lifetime discovered over 20 antibiotics.5,7  
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Less than 20 years later, Alexander Fleming, a Scottish biologist, defined new 
horizons for antibiotics with his discovery of penicillin (in 1928).8-10  Penicillin, which is 
isolated from the fungus Penicillium notatum, has been used to treat bacterial infections 
such as syphilis and gangrene.8-10  
In 1943, Selman Waksman discovered streptomycin, an antibiotic synthesized by 
the soil organism Streptomyces griseus.  It was the first major antimicrobial agent 
developed after penicillin, and the first antibiotic effective for treating tuberculosis.11-13 It 
is also used for treating infections of heart valves (endocarditis), the plague, tularemia, and 
brucellosis.12,13 
The discovery of these three antibiotics, salvarsan, penicillin and streptomycin, set 
the stage for future antibiotic research which resulted in the discovery of a large number of 
antibiotics from microbes, specifically from members of the actinomycetes and fungi 
class.14 Many antibiotics discovered up to the early 1970s reached the market, and their 
chemical scaffolds were later used as leads for creating new generations of clinically 
applicable antibiotics by chemical modification.14 Indeed, the period between 1944-1970 is 
considered to be the golden era of discovery of antibiotics.  Very few new classes have been 
discovered since then.15  
One of the most serious issues facing the medical community today is widespread 
resistance to many of the more commonly used antibiotics.  This is mainly due to the over 
use of antimicrobial drugs in many parts of the world.16-18 This has brought about the rise 
of bacteria, called “super bugs”, that are resistant to just about every antibiotic available.19 
This has resulted in warnings of a return to the pre-antibiotic era by medical experts; and a 
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recent database lists the existence of more than 20,000 potential resistance genes for almost 
400 different types or more of bacteria, predicted from available bacterial genome 
sequences.20 
The World Health Organization (WHO) created a list of several important 
antibiotics to combat super bugs. These antibiotics are called “last resort” antibiotics, which 
are only used when other more commonly used antibiotics are ineffective.  By restricting 
the use of these important antibiotics, it is expected that the bacteria will not rapidly develop 
widespread resistance to them. This leads the conversation to one of these last resort 
antibiotics, called daptomycin (Dap), which is the focus of this thesis.   
1.2 The History of Daptomycin 
Dap was first isolated from a soil bacterium Streptomyces roseosporus from Mount 
Ararat (Turkey) by researchers at Eli Lilly in the early 1980s.21,22 It was subjected to clinical 
trials; however, these clinical trials were then stopped at Phase II after patients exhibited 
high levels of creatine phosphokinase (CPK) in their system that caused muscle pain.23 In 
later years, Cubist Pharmaceuticals purchased the rights to Dap and demonstrated that the 
side effects could be minimized by altering the dose regimen.23 Dap was then approved in 
the USA by the Food and Drug Administration (FDA) in 2003 and in Europe in 2006 for 
treating severe skin infections including methicillin-resistant and susceptible 
Staphylococcus aureus (MRSA and MSSA) and vancomycin-resistant Enterococci (VRE).  
Dap is marketed under the trade name Cubicin® and was, until recently, sold by Cubist 
Pharmaceuticals which was purchased by Merck & Co. in 2014.  Unfortunately, Dap is not 
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active in vivo against community-acquired pneumonia (CAP), which could be due to the 
inhibition of Dap by lung surfactant.24  
Dap, whose structure is shown in figure 1.1, is a member of the A21978C factor 
family of calcium (Ca2+)-dependent cyclic lipodepsipeptide antibiotics (cLPAs) isolated 
from cultures of Streptomyces roseosporus.21,22 It was initially isolated as a minor 
component of the A21978C factors, but its production can be increased by supplementing 
the growth medium with decanoic acid.21,22  Dap consists of 13 amino acids, six of which 
are non-proteinogenic: D-Asn2, Orn6, D-Ala8, D-Ser11, (2S,3R)-methylglutamate 
(3MeGlu12), and kynurenine (Kyn13).25  Ten of these amino acids create the macrocyclic 
core, which is closed with a depsi-bond (ester bond) between the side chain of the threonine 
(Thr) residue at position 4 and the C-terminal of the kynurenine (Kyn) residue at position 
13. The remaining three amino acids are part of a tripeptide attached to Thr4 and attached 
to the N-terminus of the Trp1 residue is a decanoic tail.  
 
Figure 1.1.  The structure of Dap. D amino acids are shown in red. Non-proteinogenic L-
amino acids are shown in blue.   
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1.3 Daptomycin’s Mechanism of Action 
The mechanism of action (MOA) of Dap is still not known with certainty, and many 
MOAs have been proposed.26  We will not discuss all of the proposed mechanisms.  Instead 
we will focus upon those mechanisms which are supported by the most evidence.   
Using radio-labelled Dap, Canepari et al. demonstrated that Dap interacts with the 
cell wall and membrane but not with the cytosolic components.27 It is known that Dap 
requires its lipid tail for activity.25 Furthermore, the presence of the phospholipid 
phosphatidylglycerol (PG) in the bacterial membrane is also important for Dap activity.  
Dap preferentially binds to PG-enriched membrane domains in B. subtilis cells.28 Studies 
suggest that decreasing membrane PG content is a mechanism by which certain strains of 
S. aureus develop resistance to Dap.29,30  The requirement for PG may be the reason behind 
Dap’s low toxicity to humans as PG is found at very low concentrations in mammalian 
cells.31  
The requirement of PG for Dap activity has been supported by model membrane 
studies. Dap inserts into model membranes composed of phosphatidylcholine (PC) and 
phosphatidylglycerol (PG) in a calcium-dependent manner, as evidenced by a simultaneous 
increase and blue shift in the fluorescence emission signal of the Kyn residue.32 In model 
membranes containing PC and PG, a significant increase in the fluorescent quantum yield 
of the Kyn residue occurs compared to membranes containing just PC.33 This suggests that 
Kyn inserts more deeply into PC/PG membranes compared to membranes that contain only 
PC.  Using circular dichroism spectroscopy (CD), it has been shown that Dap undergoes a 
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significant conformational change in the presence of calcium and membranes that contain 
PC and PG.33  
Isothermal titration calorimetry (ITC) studies using liposomes (large unilamelar 
vesicles, LUVs) containing PC and PG have shown that Dap binds PG with a stoichiometry 
of 1:2.34 In contrast, fluorescence studies using a Dap analog containing a fluorescent label 
on the lipid tail and a lipid bicelle system found the ratio of PG to Dap to be 1:1.34 This 
discrepancy may be a result of the two techniques monitoring Dap-liposome binding at 
different stages, or perhaps Dap is interacting with only the outer leaflet of the liposome 
but with both leaflets of the bicelle.  Very recently, Huang and coworkers reported, using 
CD and small unilammelar vesicles (SUVs) containing PC and PG, that Dap binds to PG 
stoichiometrically. However, this interaction was not examined at Ca2+ concentrations 
above 100 M, and therefore may not have reached saturation.35 
Dap exhibits its maximal antibacterial effect at physiological Ca2+ concentration 
which is about 1.2 mM.21,22 Like other Ca2+-dependent cLPAs, Dap contains a highly 
conserved DXDG motif that is believed to be involved in binding Ca2+.36,37  Studies 
conducted by Grunewald et al. showed that when the aspartate residues within this motif 
are replaced with asparagine, activity is completely lost.38 This suggests that these two 
residues, Asp7 and Asp9, are important for Dap’s binding to Ca2+. 
The x-ray crystal structure of free Dap (apo-Dap), Dap bound to calcium, or of a 
Dap-calcium-PG complex has not been reported. However, the 3-D structure of free Dap 
by NMR has been reported by three different groups and all three arrived at different 
structures, probably because they were obtained under different conditions.39-41  
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The structure of Ca2+-bound Dap by NMR has also been determined by two groups 
and, again, two different structures were obtained again, under different conditions.39,40 The 
Ca2+-Dap structures and the corresponding apo-Dap structures were very similar.   
Attempts to obtain the NMR structure of Dap in the presence of Ca2+ and PG has 
not been successful mainly because of the tendency of the Dap-Ca2+-PG complexes to 
precipitate out of solution at Dap concentrations necessary for NMR studies.42 Overall, the 
NMR studies did not provide any significant insights into the MOA of Dap. 
In 1987, Allen et al. reported, using a K+ selective electrode, that Dap caused K+ 
leakage from S. aureus and this was accompanied by a collapse of the membrane potential, 
as evidenced by the release of the membrane-permeant cation tetraphenylphosphonium.43 
They also reported that Dap inhibits the cellular uptake of amino acids by active transport, 
a phenomenon that depends on the membrane potential.  These results suggested to them 
that Dap functions by permeabilizing the cell membrane, resulting in membrane 
depolarization and cell death.43   
In 2003, Silverman et al., employing a fluorescence potentiometric probe and a K+-
sensitive fluorescent probe, demonstrated that 5 g/ml of Dap triggers membrane 
depolarization and K+ release from S. aureus (at pH 7.2).44  On the basis of these results, 
and those of others such as Allen et al’s, Silverman proposed that, upon binding Ca2+, that 
Dap inserts into the cell membrane, where upon it may bind an additional Ca2+ which results 
in its oligomerization and the formation of a cation-selective pore.44 
In 2011, the Palmer group, using Dap labeled with a nitrobenzoxadiazole (NBD) 
moiety on the side chain of the Orn residue (NBD-Dap, figure 1.2), demonstrated Ca2+- and 
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PG-dependent fluorescence resonance energy transfer (FRET) between the Kyn residue 
(donor) of unlabeled Dap and the NBD residue (acceptor) of NBD-Dap in the presence of 
PC/PG LUVs.45  This suggests that Dap is oligomerizing when bound to calcium and PG 
membranes.  When just NBD-Dap was used, oligomer formation was also evident by self-
quenching of the NBD fluorescence.  Using the FRET assay, they were able to determine 
that the number of subunits contained in one Dap oligomer was approximately 6-7 in PG/PC 
(1:1) liposomes.45  They were also able to detect FRET with hybrid oligomers consisting of 
Dap and CB-182,462, a closely related Ca+2-dependent cLPA on bacterial cells and LUVs.45 
 
Figure 1.2. Structure of NBD-Dap 
The Palmer and Taylor groups also reported that an active Dap analog bearing a 
perylene acyl tail (perylene-Dap, figure 1.3) exhibited excimer fluorescence in the presence 
of PC/PG LUVs or bacterial membranes and Ca2+.46 The formation of perylene excimers 
on model membranes was inhibited by unlabeled Dap. Perylene-Dap exhibited very little 
excimer formation in the presence calcium and of LUVs that did not contain PG.46 
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Figure 1.3. Structure of the perylene-dap derivative used for excimer fluorescence studies  
The Palmer group also provided evidence that Dap can translocate between the inner 
and outer leaflets of PC/PG liposomes by showing that only 50% of the fluorescence of 
NBD-Dap bound to PC/PG liposomes can be quenched by dithionite.47 This suggests that 
one half of the NBD-Dap was in the outer leaflet and the other half was in the inner leaflet 
of the membrane where it is not accessible to dithionite.   
The Palmer group has developed an assay that allows one to detect Dap-induced 
permeabilization of LUVs for small cations, such as K+ and Na+.48,49  In this assay, the pH-
sensitive fluorophore pyranine was entrapped in PC/PG LUVs in an internal buffer at pH 6 
that did not contain the cation in question. These LUVs were diluted in an external buffer 
containing the cation in question at pH 8.  When Dap, the proton ionophore carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) and Ca2+ were added, the fluorescence 
increased, presumably due to the formation of pores by Dap which allow the external cation 
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in question to enter the liposome in exchange for protons (via CCCP).48  This results in an 
increase in the pH inside the liposome which results in an increase in the fluorescence 
intensity of pyranine (see figure 1.4 for more detail). 
 
Figure 1.4. Schematic representation of the pyranine assay for pore formation.48 (A) 
Encapsulated pyranine with a H+ gradient inside and K+ gradient outside. (B) Application 
of the protonophore CCCP alone allows insignificant loss of protons. (C) If Dap allows 
influx of the opposing K+ gradient, efflux of the proton gradient occurs increasing pH and 
causing pyranine fluorescence. Figure provided by Dr. M. Palmer. Used with permission. 
 
On the basis of the above mentioned studies, Zhang has suggested that Dap binds 
to Ca2+ and oligomerizes and forms pores in a multistep process (figure 1.5).47 First, Ca2+ 
binds to Dap, which neutralizes the negative charges in Dap and allows Dap to loosely 
associate with the membrane. Second, another Ca2+ binds to Dap which results in deeper 
membrane insertion, through a specific interaction between PG and the Dap-Ca2+ complex. 
This results in a large conformational change in Dap. Third, the inserted Dap monomers 
form oligomers which then translocate the lipid-layer and form a pore.  
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Figure 1.5. Dap mechanism proposed by Palmer and coworkers. Panels A and B show the 
tetramer formation after the binding of the first Ca2+ ion to Dap, resulting in tetramer 
formation. Panels C and D shows binding of the second Ca2+ which results in membrane 
translocation and pore formation. Figure provided by Dr. M. Palmer. Used with permission. 
 
Recently, Muller et al. proposed a different MOA for Dap.50 Using a variety of 
fluorescent lipid probes, they showed that binding of Dap to bacterial membranes led to a 
disorganization of fluid lipid domains, affecting membrane fluidity.  This led to the rapid 
detachment of lipid II synthase (MurG) and phospholipid synthase (PlsX), two enzymes 
involved in bacterial cell wall synthesis and phospholipid synthesis, from the cytoplasmic 
side of the cell membrane.  They concluded that Dap exerts its bactericidal effects primarily 
by causing the dissociation of these two enzymes from the bacterial membrane which 
disrupts cell wall synthesis.50 
Muller et al. also reported that they were unable to detect leakage of specific cations 
upon subjecting B. subtilis to sublytic concentrations of Dap (3 g/mL) for 5 min as 
determined using inductively coupled plasma optical emission spectroscopy (ICP-OES).50 
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Moreover, using a fluorescent probe and Dap concentrations that block cell growth (2 
μg/mL) but not cell lysis, they found that only incomplete membrane depolarization of B. 
subtilis occurs after 30 min.  Complete dissipation of the membrane potential only occurred 
at lytic Dap concentrations, and, even then, depolarization of the membrane was gradual 
and complete only after ∼25 min.  In contrast, the well-know pore-forming peptide, 
gramicidin S, caused almost instantaneous depolarization. On the basis of these results they 
concluded that Dap does not form specific pores.50 Although the mechanism proposed by 
Muller et al. is entirely possible, there are some issues with their study. The ICP-OES study 
was performed with only low micromolar concentrations of calcium and incubation for only 
5 min and it was already well-known that Dap does not depolarize bacterial membranes as 
rapidly as gramicidin. Dap is effective on vegetative cells and bacterial L-forms (bacteria 
that do not have a cell wall), which suggests that Dap is not involved in cell wall synthesis 
inhibition.51,52  These facts support the notion that the dislodgment of MurG is not required 
for Daps activity. On the other hand, PlsX is likely to be active in bacteriostatic cells and 
L-forms. 
1.4 The Synthesis of Dap Analogs and Structure-Activity Relationship 
(SAR) Studies 
One obvious and potentially powerful approach for studying Dap’s MOA, and for 
producing novel antibiotics with improved properties, is by performing SAR studies.  This 
requires the preparation of analogs or modified versions of Dap and then determining their 
biological activity and how they interact with bacterial membranes and/or model 
membranes. Dap analogs have been prepared by semi-synthesis and by total synthesis. 
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Since the main focus of this thesis is on SAR studies of Dap, the Dap analogs that have 
been previously constructed and studied (before the studies described in this thesis) are 
discussed in some detail below. 
1.4.1 Dap Analogs by Semi-Synthesis 
Many Dap analogs have been made by semi-synthesis. The majority of these studies have 
focused on changing the acyl tail or attaching chemical entities to the Orn residue, whose 
side chain contains the sole amino group of the entire molecule.  
Modification of the acyl tail involves first protecting the Orn reside with a Boc 
group and then de-acylating (removing the decanoyl tail) from the resulting protected Dap 
using a de-acylase.  The resulting free amino group is reacted with activated esters of 
carboxylic acids and then the Boc group is removed.53 This approach has been used to 
prepare surotomycin, which contains an (E)-3-(4-pentylphenyl)but-2-enoyl tail. 
Surotomycin has high activity against Clostridium difficile.  Unfortunately, it failed to be 
non-inferior to current therapies in Phase III clinical trials and so further studies on this 
antibiotic were discontinued.54  
Many Dap analogs have been made by attaching chemical entities to the Orn residue 
using a variety of different chemical procedures.55,56 None of these compounds made it to 
human clinical trials, though several had in vitro activity equal to or better than Dap.  These 
results suggested that the Orn residue is not essential for antibacterial activity.  
The Trp residue in Dap has been replaced with a range of natural and unnatural 
aromatic amino acids.57 They were prepared by first protecting the Orn reside with an 
allyloxy group. The decanoyl tail was then removed enzymatically, followed by removal 
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of Trp1 by Edman degradation and then attachment of the N-protected unnatural aromatic 
amino acid to the N-terminus of the Asn residue.  The N-protecting group on the unnatural 
amino acid residue was removed, the decanoyl tail was attached to the resulting free amino 
group, and the allyl group removed from the Orn residue. Several of these analogs exhibited 
activity close to that of Dap and also had increased activity in the presence of lung surfactant 
compared to Dap.  These results suggest that the Trp residue is not essential for activity.57 
1.4.2 Total Synthesis of Dap Analogs 
 The total synthesis of Dap analogs has been achieved using three different 
approaches: chemo-enzymatic synthesis, combinatorial biosynthesis and total chemical 
synthesis. 
1.4.2.1 The Chemo-Enzymatic Approach to Dap Analogs 
The earliest approache used for preparing Dap analogs is the chemo-enzymatic 
approach. In this approach, solid phase peptide synthesis (SPPS) is used to prepare a linear 
Dap analog having a thioester C-terminus.  After removal from the solid support and HPLC 
purification, the resulting thioester peptide is cyclized using a thioesterase/cyclase. In 2004 
and 2006 Grunewald, et al. reported the synthesis and biological activity of nine Dap 
analogs using this approach.38,58 The analogs that were prepared and tested are shown in 
table 1.1.  
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Table 1.1. MIC’s of the analogs created by the 
chemo-enzymatic approach.  
Entry Compound MIC (μg/mL)a 
1 Dap-L-N2-E12 20 
2 Authentic Dap 3 
3 Dap- L-N2-N3-E12 80 
4 Dap- L-N2-N7-E12 >960 
5 Dap- L-N2-N9-E12 >960 
6 Dap- L-N2-Q12 30 
7 Dap- L-N2-D11-E12 >320 
8 Dap- L-N2-E12-W13 100 
9 Dap- L-N2-K6-E12-W13 100 
a The analogs were tested against B. subtilis PY79 at 
73.6 mg/L calcium.38,58 
 
At the time of this work, Asn2 in Dap was believed to be an L amino acid, and so 
L-Asn was used. It was later determined that Dap contains D-Asn at this position.59 
Moreover, in all of their analogs, 3MeGlu13 was replaced with Glu, since the synthesis of 
3MeGlu with the correct stereochemistry is labour-intensive. Consequently, most of their 
Dap analogs were triple mutants containing Glu in place of 3-MeGlu12, the unintended L-
Asn2 substitution, and the substitution of interest at a third position within the peptide. 
Perhaps the most significant information obtained from these studies was that when Asp 7 
or Asp 9 were replaced with Asn, all activity was lost (entries 4 and 5).  Asp7 and Asp9 are 
believed to be important for Ca2+ binding, as they are part of the DXDG sequence found in 
the EF hand motif of many calcium binding proteins as mentioned earlier. These results 
support this supposition.  The relatively minor decrease in activity found when Asp3 and 
3MeGlu12 were replaced with Asn and Gln, respectively (entries 3 and 6 in Table 1.4) 
suggests that these residues are not directly involved in Ca2+ binding.  
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This chemoenzymatic approach to Dap analog synthesis has some drawbacks.  One 
is that the cyclases are non-specific.  Moreover, the overall yields can be quite low.  Finally, 
the peptides have to be purified by HPLC both before and after cyclization, which does not 
make it a very practical approach to making large numbers of analogs. 
1.4.2.2 The Biosynthetic Approach to Dap Analogs 
Dap is naturally produced by Streptomyces roseosporus via several non-ribosomal 
peptide synthetases (NRPSs).60,61 Three large, multifunctional, synthetase enzymes, DptA, 
DptBC and DptD, govern its assembly (figure 1.6).61 Each synthetase contains several 
modules and each module has a condensation-adenylation-thiolation (CAT) domain and 
each module incorporates an amino acid. There is also an optional epimerization (E) 
domain. An enzyme called DptE that initiates the synthesis by activating decanoic acid in 
an ATP-dependent manner. The activated decanoic acid is then transferred to an enzyme 
called DptF. The C-domain of DptA catalyzes the condensation between the enzyme-bound 
decanoyl tail and tryptophan. After this initial condensation, the peptide chain is elongated 
by DptA, DptBC, and DptD operating in a linear fashion. Once the linear peptide chain is 
completed, the thioesterase (TE) in DptD directs the intramolecular attack of the hydroxyl 
group of threonine on the carbonyl of the enzyme-bound thioester.  This leads to cyclization 
and release of the cyclic lipopeptide. 60,61 
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Figure 1.6.  The biosynthesis of Dap. See text for details. The figure was used with 
permission.61 
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Dap analogs have been prepared by combinatorial biosynthesis.59,62,63 In this 
approach, the modules responsible for the incorporation of the amino acids are swapped 
with NRPS systems encoding similar, naturally occurring lipopeptides. Cubist 
Pharmaceuticals used this approach to prepare analogs of Dap.  Their objective was to 
prepare a Dap analog that remained active in the presence of lung surfactant.59  The Dap 
analogs created by this approach and their MIC’s against S. aureus in the absence and 
presence of synthetic lung surfactant are given in table 1.2. 
Table 1.2.  Dap analogs created through combinatorial biosynthesis and their MIC’s 
against S. aureus in the absence and presence of lung surfactant.  
 
a Dap or Dap analog. bAmino acid changes are shown in bold italics. c MICs were 
determined against S. aureus in the presence or absence of 1% synthetic lung surfactant. 
Reprinted with permission from Baltz, R. H. Am. Chem. Soc. – Synth. Biol. 2014, 3, 748-
758. Copyright 2014, American Chemical Society. 
 
When Kyn13 was replaced with a other hydrophobic residues (Trp, Ile, Val) the 
activity in the absence of surfactant decreased 2 to 8-fold, while the activity in the presence 
of lung surfactant increased.  The W13 mutant was only 2-fold less active than Dap itself. 
The N13 mutant was almost devoid of activity, suggesting that a non-polar residue is 
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necessary at this position. Replacing 3MeGlu12 with Glu reduced the activity 16-fold, but 
the activity in the presence of surfactant increased 4-fold. Interestingly, substituting D-
Ser11 with D-Ala or D-Asn resulted in almost no loss of activity in the absence of surfactant 
and a 4-fold increase in activity in the presence of surfactant.  This suggests that D-Ser11 
is not required for activity and suggests that this position is a potential site for further 
modification. 
Although Dap analogs can be prepared using combinatorial biosynthesis, there are 
several shortcomings that limit the usefulness of this approach. Combinatorial biosynthesis 
is dependent on specificity of the host organism for certain modules, with no guarantee that 
added modules will be accepted by this bacterium. Although some amino acid substitutions 
can be made, no dramatic changes can be done. For example, Cubist Pharmaceuticals was 
unable to exchange 3MeGlu12 for anything other than Glu.59 It was also not possible to 
alter the stereochemistry of the residues.  
1.4.2.3 Dap Analogs by Total Chemical Synthesis  
The first total chemical synthesis of Dap was achieved in 2013 by Lam, et al.64 The 
most challenging aspect of the synthesis was formation of the ester bond.  They were unable 
to form the ester bond between Thr4 and Kyn13 either on a solid support or even in solution.  
Instead, they had to prepare a tetrapeptide in solution which contained an ester linkage 
between the -COOH group of a Trp residue and the side chain of Thr4.  The Trp residue 
was then converted to a Kyn residue by ozonolysis.  The resulting tetrapeptide was used as 
a building block in their solid phase synthesis of a linear, branched, uncyclized precursor. 
After cleavage from the support the uncyclized peptide was purified by HPLC then cyclized 
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via a solution phase serine ligation reaction.64  This combination of solid and solution phase 
chemistry made for a very laborious synthesis and is therefore not well suited to the 
preparation of large numbers of analogs.  
In 2014, Martin, et al. reported the total chemical synthesis of two Dap analogs and 
their enantiomers.65 Branched, acyclic versions of the Dap analogs were prepared in the 
solid phase, which, after cleavage from the solid support, were cyclized in solution.  Each 
one had a diaminopropionic acid (DAPA) residue in place of Thr4. This resulted in the ester 
bond in Dap being replaced with an amide bond. One analog contained DAPA and Glu in 
place of 3MeGlu at position 12 (entry 2, table 1.3). Another contained DAPA, Glu at 
position 12 and Trp at position 13 (entry 3, table 1.3). The other two analogs were the 
enantiomers of these analogs (entries 4 and 5, table 1.3). The analogs containing the natural 
stereochemistry were 100-200 times less active than Dap, indicating that the ester bond 
and/or the methyl group of the Thr side chain is crucial for activity. The enantiomers of 
these analogs were inactive, which suggests that Dap is interacting with a chiral target such 
as a chiral lipid (perhaps PG), or a protein (such as Plsx). 
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Table 1.3. MIC’s of the analogs created by the 
synthetic approach by Martin, et al.  
Entry Compound MIC (μM)a 
1 Daptomycin b 3 
2 Dap-DAPA4-E12 201 
3 Dap-DAPA4-E12-W13 101 
4 Dap-DAPA4-E12 (ent) Not active 
5 Dap-DAPA4-E12-W13 (ent) Not active 
aTested against S. aureus ATCC 29123 at 50 mg/L 
calcium. bIsolated for natural source. 
 
In 2015, the Taylor group published the first total synthesis of Dap performed 
entirely on the solid phase (scheme 1.1).66,67 As this synthesis and subsequent routes to Dap 
developed in the Taylor group are very relevant to this thesis, these syntheses are in some 
detail below.  
The original route planned by Taylor to synthesize Dap is shown in scheme 1.1.  
Dipeptide 1.1, which consists of Asp9 and Gly10, was attached to chlorotrityl resin via the 
side chain of the Asp residue. Fmoc SPPS was used to prepare peptide 1.2. Unfortunately, 
they were unable to make the ester bond between the Thr4 side chain in peptide 1.2 and 
FmocKyn(Boc, CHO)OH to get peptide 1.3. This forced them to design an alternative route 
to Dap.   
 
Scheme 1.1. First attempt by the Taylor group to prepare Dap by Fmoc SPPS. 
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In the revised route (scheme 1.2), peptide 1.4 was prepared using Fmoc SPPS.  
N3Asp(tBu)OH (an azido acid) was attached to this peptide to give peptide 1.5.  Because 
peptide 1.5 did not contain Asn2, Trp1 and the decanoyl tail, which had been found to 
interfere with ester bond formation, it was possible to make the ester bond between 
FmocKyn(Boc,CHO)OH and the side chain of Thr4, using the symmetric anhydride of 
FmocKyn(Boc,CHO)OH, to give peptide 1.6 in quantitative yield. The azido group in 
peptide 1.6 was reduced to the amine using PMe3 in dioxane/water and then Asn2 was 
installed as an azido acid. The azido group on the Asn residue was reduced as before and 
then Trp1 was installed as an azido acid, followed by azido group reduction and installation 
of the decanoyl tail to give peptide 1.3. The Fmoc group on peptide 1.3 was removed and 
then 3MeGlu12 and Ser11 were installed using Fmoc SPPS to give peptide 1.7.  The allyl 
group was removed from Gly10 and the resulting peptide 1.8 was cyclized on resin to give 
1.9. As the cyclization involved activation of Gly10, no racemization occurred during the 
cyclization process. After removal of all the protecting groups and cleavage from the resin 
using TFA, Dap was obtained in a 3.7 % overall yield.  
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Scheme 1.2.  The total solid phase synthesis of Dap by the Taylor group 
In addition to Dap itself, several Dap analogs were synthesized using the approach 
outlined in scheme 1.2 and their activity tested against two B. subtilis strains (table 1.4).66 
When the stereochemistry of the side chain of 3MeGlu was reversed (entry 2, table 1.4), 
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the activity was greatly reduced. It has been observed previously that the substitution of 
3MeGlu with Glu decrease activity while substitution of Kyn13 with Trp had little effect 
on activity.58,63 Unexpectedly, when both were simultaneously replaced (Dap-E12-W13, 
entry 3, table 1.4), the activity was approaching that of Dap at 5 mM calcium.  When both 
3MeGlu and Kyn13 were replaced with Glu and Tyr respectively, the activity was much 
below that of Dap (entry 4, table 1.4).  Surprisingly, all of the analogs were found to be 
much more active at high Ca2+ ion concentrations (25 and 100 mM).  This suggests that 
these substitutions reduce Dap activity, at least in part, by reducing calcium affinity.66,67 
Table 1.4.  MIC’s of the analogs created by the route outlined 
in scheme 1.2 by Taylor and coworkers. 
  MIC (μg/mL) 
 
Entry 
 
Compound 
B. subtilis 
ATCC 1046 
B. subtilis 
PY79 
1 Daptomycin 0.75a, 0.5b,c 0.75a 
2 Dap-(2S,3S)-MeGlu 40a, 5.0b, 5.0c >40a 
3 Dap-E12W13 1.5a 3.0a 
4 Dap-E12Y13 35a, 3.0b, 1.3c ND 
 a5 mM Ca2+. b25 mM Ca2+. c100 mM Ca2+  
One drawback to the synthesis outlined in scheme 1.2 was that it utilized three azido 
acids as building blocks. Azido acids are not commercially available and have to be 
synthesized.  This provided the impetus for the Taylor group to design an improved 
synthesis of Dap analogs that required only a single azido acid.66,67 This approach is 
outlined in scheme 1.3 for the synthesis of Dap-E12W13. In this approach, Trp13 is 
introduced into peptide 1.11 (from peptide 1.10) as an azido acid.  Asn2, Trp1 and the 
decanoyl tail are then installed using standard Fmoc SPPS to give peptide 1.12.   
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Scheme 1.3.  Taylor and coworkers improved synthesis of Dap-E12-W13. 
The reduction of the azido group in peptide 1.12 to give peptide 1.13 was preformed 
using unusual conditions: 5 equiv of the symmetric anhydride of FmocGlu(tBu)OH, 3 equiv 
Bu3P, in THF for 5 min followed by the addition of water and shaking for 18 h.  The 
Bu3P/water should reduce the azido group to give the amine, which one would expect would 
react with the symmetric anhydride of FmocGlu(tBu)OH; this in turn should result in the 
incorporation of Glu12 into peptide 1.12.  However, this does not occur.  The azido group 
is reduced to the amine but Glu12 is not installed.  Peptide 1.13 is almost the sole product.68 
If the reduction is done using standard reduction conditions (PMe3 or PBu3 in dioxane/water 
or DTT/DIPEA) then a side reaction occurs in which 50% of the ester bond in peptide 1.12 
is cleaved and peptide 1.14 and triazole 1.15 are produced (scheme 1.4) in  1:1 ratio.68  
26 
 
 
Scheme 1.4.  Cleavage of the ester bond in peptide 1.12 using standard azido group 
reduction conditions. 
 
 This side reaction is a result of the intermediate aminophosphorane cyclizing and 
attacking the carbonyl carbon of the ester bond followed by loss of peptide 1.13 and 
formation of triazole 1.14 (scheme 1.5).68,69 
 
Scheme 1.5. Proposed mechanism for the formation of peptide 1.14 and triazole 1.15.  
Using the approach outlined in scheme 1.3, several new Dap analogs, based upon 
Dap-E12-W13, were prepared in yields as high as 20 % (table 1.5).66,67 When 3MeGlu was 
replaced with Gln, Thr4 replaced with Ser, or Asp3 replaced with Glu (entries 2, 3 and 4 in 
table 1.5), the resulting analogs were considerably less active than Dap at 5 mM Ca2+ but 
almost as active as Dap at 100 mM Ca2+.  However, when Asp7 was replaced with Ala 
27 
 
(entry 5, table 1.5), activity was completely lost, even at high Ca2+ concentrations. This 
supports the supposition that this amino acid is directly involved in binding Ca2+ as 
discussed in sections 1.3 and 1.4.2.1. The poor activity of the Ser4 analog revealed that the 
methyl group on the side chain of Thr4 is essential for good activity.   
Table 1.5. MIC’s of the analogs created by the route 
outlined in scheme 1.3 by Taylor and coworkers. 
  MIC (μg/mL)a 
Entry Compound 1.8b 5.0b 100.0b 
1 Daptomycin 1.0 0.75 0.5 
2 Dap-Q12W13 ND 7 0.75 
3 Dap-S4E12W13 >100 65 3 
4 Dap-E3E12W13 >100 40 1.5 
5 Dap-A7E12W13 >100 >100 >100 
aAgainst B. subtilis ATCC 1046. bCalcium concentration 
 
1.5 Proposed Mechanisms of Resistance to Daptomycin 
Although clinical isolates of Dap-resistant bacteria are still relatively rare, they are 
appearing with greater frequency. This is a cause for concern as Dap is a last resort 
antibiotic.  If widespread resistance to last resort antibiotics occurs, few alternatives are 
available. If it can be determined how bacteria develop resistance to Dap, then this 
information might provide vital clues to elucidating Dap’s MOA, and it may be possible to 
rationally develop Dap analogs that retain activity against bacteria resistant to native Dap.  
Some of these resistance mechanisms are discussed below. 
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Mutations in the pgsA gene have been shown to occur in Dap-resistant B. subtilis and 
S. aureus.28-30 The pgsA gene encodes a phosphatidyl transferase that is involved in the 
biosynthesis of PG. These mutations might cause a decrease in the amount of PG in the 
membrane, which would decrease the effectiveness of Dap. 
Isolates of S. aureus that are resistant to Dap show an increase in the percentage of 
lysyl-PG in the cell membrane.70-72 Lysyl-PG is a common phospholipid commonly found 
in Gram-positive bacteria. These Dap-resistant bacteria up-regulate a protein called MprF. 
Depletion of MprF causes hypersensitivity to Dap.71 MprF converts PG to lysyl-PG and 
then flips the lysyl-PG to the outer leaflet of the cell membrane. Lysyl-PG bears a positive 
charge; in contrast, PG bears a negative charge.  Therefore, an increase in the amount of 
lysyl-PG in the cell membrane results in an increase in the positive charge on the surface 
of the cell membrane. It has been proposed that this affects the ability of Dap to interact 
with the membrane.  However, Mishra et al. found that not all mutations in MprF alter the 
membrane charge ratio.71 Therefore it is possible that up regulation of MprF simply results 
in a reduction of the percentage of PG in the membrane.  
In E. faecium, mutations in yycFG operon, which encodes two proteins called YycG 
and YycF, have been found in Dap-resistant strains.73 Dap-resistant mutants of S. aureus 
derived in vitro exhibited changes affecting the histidine kinase of the system (YycG).70,74 
TycG and YycF are part of a regulatory system required for viability in Gram-positive 
bacteria. In B. subtilis, YycG is localized to the cell division septum where it regulates cell 
division and cell wall restructuring.75 Baltz has suggested that there is a relationship 
between YycG and Dap’s MOA.60 First, Dap and YycG are found near the cell division 
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septum of bacteria. Second, both Dap-treated bacteria and bacteria depleted of YycG have 
also been shown to exhibit minor morphological changes in both S. aureus and B. subtilis, 
leading to unnatural division septa. Third, the depletion of YycG has been shown to cause 
cell death without lysis, like Dap. Fourth, the YycFG system positively regulates biofilm 
formation while Dap treats S. aureus biofilms effectively. Baltz therefore suggested a dual 
mechanism of action for Dap: disruption of YycG and membrane depolarization.  
When B. subtilis was treated with Dap, the expression of a membrane-associated 
transcriptional regulator called LiaRS increased >400 fold.28,76 This two-component 
regulator is thought to be involved in the cell membrane adaptive responsive to antibiotics. 
Arias et al. characterized several LiaRS mutations found in clinical isolates of E. faecalis 
and E. faecium that induce resistance to Dap.77 When LiaRS was activated, the expression 
of two proteins called LiaI and LiaH were greatly increased.77 These proteins are known to 
segregate to separate domains of the plasma membrane but their role in Dap resistance is, 
to date, unknown. Friulimicin, another Ca2+-dependent lipopeptide antibiotic was found not 
to up-regulate the production of LiaRS which suggests that Dap’s activation of these 
proteins regulator is specific.76  
Tran, et al. noted that some non-clinical isolates of some bacteria have developed 
enzymes that hydrolyze the ester bond in Dap, thus destroying the antibiotic.78 This mode 
of resistance has not been found to occur in clinical isolates to date. 
Up-regulation of the dlt operon has been found to occur in Dap-resistant S. aureus 
strains.79-82 Proteins coded by the dlt operon are involved in the attachment of D-alanine to 
cell wall teichoic acids of Gram-positive bacteria. This results in LTA bearing a positive 
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charge (from the -amino group of alanine). It has been suggested that this could repel Dap 
from the membrane, reducing Dap’s activity. 
1.6 Research Objectives and Thesis Overview 
There are two objectives of the work presented in this thesis.  The first is to ascertain 
the functional contribution of each amino acid residue at each successive stage of Dap 
action, that is, in membrane binding, oligomerization, and pore formation.  Towards this 
end, in chapter 2, an alanine scan was performed on Dap-E12-W13, in which each amino 
acid was substituted with Ala.  The resulting Dap analogs were then assessed for their 
biological activity and interaction with model membranes in the presence of Ca2+.  The 
second objective is to develop a Dap analog with improved activity. Since the results from 
the alanine scan identified position 11 as one possible site for modification, Ser11 was 
replaced with 17 other common amino acids and the resulting Dap analogs were then 
assessed for their biological activity and their ability to interact with model membranes in 
the presence of calcium.  These studies are still ongoing in the Taylor group. 
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Chapter 2 
An Alanine Scan of Daptomycin 
2.1 Introduction 
 In Chapter 1, section 1.4, it was discussed that only limited SAR studies have been 
performed on Dap to date.  More in-depth SAR studies would be helpful towards resolving 
Dap’s MOA, and for the development of Dap analogs that are active against Dap-resistant 
bacteria and/or can function in the presence of lung surfactant.   
In this chapter, an attempt is made to answer the following questions about Dap:  
Which amino acids in Dap are amenable to substitution? In other words, which amino acids 
can be substituted with another amino acid without significantly adversely affecting Dap’s 
biological activity?  Which amino acids effect Dap’s ability to interact with membranes?  
Is there a correlation between biological activity and calcium affinity and membrane 
binding? 
One approach that has been used extensively in biochemistry to determine the 
contribution of certain residues to a protein’s activity and action mechanism is to perform 
an alanine scan. In an alanine scan, each residue in question is replaced with alanine one-
at-a-time and the effect of the substitution on the activity of the resulting peptide is assessed.  
Alanine is chosen because it is small and inert, and its main effect usually consists in the 
removal of the specific features of the residue it replaces. Alanine scans have been used to 
investigate the contribution of residues to the activity and mechanism of action of peptide 
antibiotics. For example, an alanine scan of the clinically important cationic cLPA 
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polymyxin revealed how much each of its residues contributes to its biological activity and 
its association with lipopolysaccharides, polymyxin’s biological target.83  
In this chapter, we attempt to answer the above questions by performing an alanine 
scan on Dap-E12-W13.  Dap-E12-W13 was used instead of Dap for these studies because 
it does not contain 3MeGlu at position 12, which is very labor intensive to prepare, yet it 
exhibits biological activity approaching that of Dap at 5 mM Ca2+.  The in vitro antibacterial 
activity of the Dap analogs prepared in this study was determined.  To determine which 
amino acids effect Dap’s ability to interact with membranes and if there is a correlation 
between biological activity and membrane binding, each analog was examined for its ability 
to interact with model liposomes in the presence of varying amounts of Ca2+.   
2.2 Materials and Methods 
2.2.1 Chemicals and Instruments 
2'-Chlorotrityl chloride polystyrene resin (2ClTrt-PS, 1.5 milliequiv/g) and 2'-
chlorotrityl chloride Tentagel resin (2ClTrt-TG, 0.19 millequiv/g) as well as all Fmoc 
amino acids, reagents and solvents used for SPPS were purchased from commercial 
sources, such as, Combi-Blocks, Creosalus, and Chem-Impex Int’l Inc. All used without 
further purification unless stated otherwise. Dichloromethane (DCM) was distilled from 
calcium hydride under nitrogen.  Manual peptide syntheses were performed manually using 
a rotary shaker for agitation.84   Automated peptide synthesis was performed on a Protein 
Technologies Quartet peptide synthesizer. High performance liquid chromatography 
(HPLC) was performed using a Waters 600 System equipped with a UV detector set to 220 
nm.  A Higgins Analytical Inc. (Mountainview, CA, USA) Clipeus C18 column (10 µM, 
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250 x 4.6 mm) was used for analytical HPLC at a flow rate of 1.0 mL/min. A Higgins 
Clipeus C18 column (10 µM, 250 x 20 mm) was used for semi-preparative HPLC at a flow 
rate of 10 mL/min.  All HPLC chromatograms shown in the appendix section were obtained 
using a linear gradient of 10% acetonitrile (ACN)/90% H2O (0.1% TFA) to 90% acetonitrile 
(ACN)/10% H2O (0.1% TFA) over 50 min. High resolution positive ion electrospray 
(ESI+HRMS) mass spectra (see appendix A and C) were obtained using a Thermoscientific 
Q-Exactive orbitrap mass spectrometer.  1:1 MeOH/H2O + 0.1% formic acid was used as a 
solvent for HRMS. 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-
dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt; DMPG), 1,2-dioleoyl-sn-
glycero-3- phosphocholine (DOPC), and 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-
glycerol) (sodium salt; DOPG), whose structures are shown in figure 2.1, were obtained 
from Avanti Polar Lipids (Alabaster, Alabama).  Large unilammelar vesicles (LUVs) were 
prepared by using equal proportions of phosphatidylcholine (PC) and phosphatidylglycerol 
(PG) lipids. They were then added to a round bottom flask and dissolved in 3 mL 
chloroform. The dissolved lipids were dried under purified nitrogen and kept under high 
vacuum overnight. The dried lipid film was then suspended in HEPES-buffer (20 mM 
HEPES, 150 mM NaCl, pH 7.4) and vortexed until all lipids were detached from the flask 
and suspended in buffer. These multilamellar vesicles were extruded under pressurized 
nitrogen through polycarbonate membranes (0.1 nm in diameter), fifteen times, to produce 
LUVs.   
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Figure 2.1.  Structure of PC (phosphatidylcholine) and PG (phosphatidylglycerol) lipids. 
 
2.2.2 General Procedure for the Synthesis of Dap Analogs 
 Peptide 2.1 (scheme 2.1),66,67 which contains residues 9 and 10, was used for the 
preparation of all analogs with the exception of Dap-A10-E12-W13.  2ClTrt-PS (133 mg, 
0.200 mmols), 2ClTrt-TG (526 mg, 0.100 mmols) or Rink Amide-PS were used as resins.  
For the synthesis of Dap-A10-E12-W13, the Gly residue in peptide 2.1 was replaced with 
Ala.  Residues 8 to 1 were incorporated using standard Fmoc SPPS using Fmoc amino acid 
(4 equiv), O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU, 4 equiv) and 4-methylmorpholine (4 equiv) in 
dimethylformamide (DMF, 1.5 mL) and 1 h coupling times.  After each coupling the resin 
was filtered and washed with DMF (3 x 3 min) and DCM (3 x 3 min).  FmocThrOH was 
used for the incorporation of Thr4. The Fmoc group was removed with 20% 4-
methylpiperidine in DMF (1.5 mL, 1 x 5 min).  The resin was washed with DMF (1 x 15 
min, 3 x 3 min) and DCM (3 x 3 min) after each deprotection. The decanoyl tail was 
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introduced using decanoic acid (4 equiv), diisopropylcarbodiimide (DIC, 4 equiv) and 
hydroxybenzotriazole (HOBt, 4 equiv) in DMF (1.5 mL) for 13 h followed by the usual 
washing procedure. The depsi bond was introduced by first reacting either 
FmocTrp(Boc)OH (10 equiv) or FmocAlaOH (10 equiv) and DIC (10 equiv) in dry DCM 
(2 mL) for 35 min.  This mixture was then added to the swollen resin-bound peptide. DMAP 
(0.1 equiv) was added followed by the addition of Triton X-100 (20 L) (unless stated 
otherwise in Table 1) and the mixture was agitated for 13 h.  The mixture was filtered and 
washed with DMF (3 x 3 min) and DCM (3 x 3 min).  The coupling was repeated if the 
efficiency of the reaction was less than 80 % (see Table 1 for the number of couplings used 
for each analog).  Residues 12 to 11 were incorporated using standard Fmoc SPPS using 
Fmoc amino acid (4 equiv), 4 equiv DIC (4 equiv) and 4 equiv HOBt (4 equiv) in DMF 
(1.5 mL) and 3-4 h coupling times.  After each coupling the resin was filtered and washed 
with DMF (3 x 3 min) and DCM (3 x 3 min).  For residues 12 and 11, the Fmoc group was 
removed using 20% 2-methylpiperidine in DMF (1.5 mL, 3 x 10 min) followed by the usual 
washing procedure.  The alloc group was removed using dimethylbarbituric acid (DMBA, 
10 equiv) in the presence of a catalytic amount of Pd(PPh3)4 in DCM:DMF (3:1 v/v, 2 mL) 
for 50 min.  The resin was filtered and washed with DCM (3 x 3 min), and then with a 1.0 
% solution of sodium diethyldithiocarbamate trihydrate in DMF (2mL, 3 x 15 min) to 
remove excess Pd catalyst, and then DMF (3 x 3 min) and DCM (3 x 3 min). On resin 
cyclization was performed using (7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium 
hexafluorophosphate (PyAOP)/1-Hydroxy-7-azabenzotriazole (HOAt)/2,4,6-collidine 
(5/5/10 equiv) with 1% Triton X-100 in DMF (2 mL) (2 x 1.5 h).  Crude analog was 
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obtained by treating the resin-bound peptides with a solution of trifluoroacetic acid (TFA): 
triisopropylsilane (TIS): H2O (95:2:5:2.5, 2 mL) for 2 h.  The mixture was filtered, and the 
resin was rinsed with DCM.  The combined filtrates were concentrated to one fourth the 
original volume using a stream of N2 gas. The peptide was precipitated by adding cold ether 
(3 mL). The precipitated peptide was collected by centrifugation and washed twice with 
cold ether.  Pure analog obtained using semi-preparative HPLC employing a linear gradient 
of ACN/H2O (0.1% TFA) (70% Acetonitrile and 30% H2O (0.1% TFA) to 35% Acetonitrile 
and 65% H2O (0.1% TFA) in over 50 min). Fractions containing the desired analog were 
collected, concentrated by high vacuum and lyophilized to give pure analog as a white 
powder (see Appendix A for the analytical HPLC chromatograms and HRMS spectra for 
each analog).  
2.2.3 Antibacterial Activity 
The minimum inhibitory concentration (MIC) of the Dap analogs against B. subtilis strains 
were determined as previously described by Muraih et al using serial dilutions in microtiter 
plates..85 Each reported MIC is the average of three determinations. 
2.2.4 Liposome Binding Studies  
Liposome binding studies were performed as previously described by Muraih et 
al.85 To a suspension of DMPG/DMPC or DOPG/DOPC (1:1) LUVs (250 M total lipid) 
in HEPES (20 mM, pH 7.4)/NaCl (150 mM), was added Dap, or Dap analog (3 M final 
concentration). A solution of CaCl2 was added to the final concentrations indicated in 
Figure 2.2 (0-100 mM). Samples were incubated at 37 °C for 3 minutes. Fluorescence 
spectra were acquired on a PTI QuantaMaster 4 instrument (excitation wavelength: 365 nm; 
37 
 
emission wavelength: 400-600 nm for Dap; excitation wavelength: 280 nm; emission 
wavelength: 300-400 nm for the Dap analogs). (see Appendix B for the fluorescence spectra 
and membrane binding curves (MBCs) for each analog).  
 
2.3 Results and Discussion 
2.3.1 Synthesis of Dap-E12-W13 Analogs 
In Chapter 1, we presented two different routes (schemes 1.2 and 1.3) to Dap that 
were developed in the Taylor group.66,67 Each route utilized at least one azido acid as a 
building block. However, it was desirable to have a route to Dap that does not require any 
azido acids and relies solely on Fmoc building blocks as they are commercially available 
while azido acids are not.   
One of the Dap analogs that the Taylor group wished to prepare was one in which 
all of the uncommon amino acids (not including the D amino acids), Orn6, 3MeGlu12, and 
Kyn13, are replaced with one of the common 20 amino acids.  In Dap-E12-W13, a fairly 
active Dap analog, 3MeGlu12 and Kyn13 in Dap are replaced with Glu and Trp.  Hence, 
all that was left was replacing the Orn residue in Dap-E12-W13 with Lys.  The synthesis of 
this analog, Dap-K6-E12-W13, was undertaken by Dr. Chuda Lohani in the Taylor group.  
While working on the synthesis of this analog, he revisited the route outlined in scheme 1.1 
as it was designed to use only Fmoc building blocks.  Using equimolar quantities of 
FmocTrp(Boc)OH (10 equiv) and DIC (10 equiv), cat. DMAP (0.1 equiv), 0.1 % triton X-
100, in CH2Cl2, he was able to prepare peptide 2.3 from peptide 2.2 after one overnight (16 
h) coupling with almost no epimerization (scheme 2.1).  Peptide 2.3 was then carried 
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forward to give Dap-K6-E12-W13 in over a 20 % yield.  It is worthy of note that these 
conditions for forming the ester bond are also capable of forming the ester bond between 
FmocKyn(Boc,CHO)OH and peptide 1.2 (Chapter 1, scheme 1.1); however, the resulting 
peptide, 1.3, is formed as a 2:3 mixture of epimers.   
 
Scheme 2.1. Synthesis of Dap-K6-E12-W13. 
The approach used to prepare Dap-K6-E12-W13 in scheme 2.1 was applied to the 
synthesis of Dap-E12-W13 (scheme 2.2).  The synthesis was initiated by attaching a 
suitably protected Asp9Gly10 dipeptide (2.1) to 2-ClTrtCl polystyrene resin (2-ClTrtCl-
PS) via the side chain of the Asp residue.  Fmoc-based SPPS was used to introduce residues 
1-8 using Fmoc amino acid (4 equiv), using O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU, 4 equiv) and 4-methylmorpholine (4 
equiv) as coupling agent. The decanoic tail was introduced using decanoic acid (4 equiv), 
diisopropylcarbodiimide (DIC, 4 equiv) and hydroxybenzotriazole (HOBt, 4 equiv).  
FmocTrp(Boc)OH was successfully coupled to the side chain of Thr4 in peptide 2.4, using 
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DIC/HOBt/cat. DMAP in DCM to give the desired peptide, 2.5, in quantitative yield. It was 
found that the esterification could be achieved equally well with or without Triton.  Fmoc 
SPPS was used to introduce residues 12 and 11 using 2-methylpiperidine (2-MP) for Fmoc 
removal to minimize C-O bond aminolysis. The allyl group in Gly10 was then removed 
using dimethylbarbituric acid (DMBA) and cat. Pd(PPh3)4.  The resulting peptide, 2.6, was 
cyclized using PyAOP/HOAt/2,4,6-collidine in DMF with 0.1 % Triton X-100 (called the 
magic mixture).86 Pure Dap-E12-W13 was obtained after side chain deprotection and 
cleavage from the resin and HPLC purification of the resulting crude peptide. 
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Scheme 2.2.  Synthesis of DapE12W13 using the improved route. 
The route outlined in scheme 2.2 was then applied to the synthesis of Dap-A6-E12-
W13. When the esterification was done in the absence of Triton, 20% of unesterified 
peptide remained after two 13 h couplings.  In the presence of 0.1 % Triton. the depsi bond 
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was formed with almost 100% efficiency after two 13 h couplings with very little 
epimerization. We also prepared Dap-A6-E12-W13 on TentaGel (2ClTrt-TG) resin. 
TentaGel resin is a copolymer consisting of a low crosslinked polystyrene matrix on which 
poly (ethylene glycol) (PEG) is grafted.  Difficult couplings tend to proceed more readily 
on TentaGel as PEG is more hydrophilic than polystyrene and the PEG linker allows for 
more space between the resin and the peptide. Overall, this results in less peptide 
aggregation during SPPS and hence better coupling yields. For the synthesis of Dap-A6-
E12-W13 on Tentagel resin, the esterification reaction proceeded with almost 100% 
efficiency after two 13 h couplings with or without 0.1 % Triton.   
The procedure described in scheme 2.2 was then applied to the synthesis of the rest 
of the Ala variants (table 2.1).  L- and D-Ala was used as appropriate so as to preserve the 
regular stereochemistry of the residue in question. The D-Ala residue at position 8 was 
substituted with L-Ala, and Asp9 was converted to an Asn residue using a Rink amide linker 
on polystyrene. Obviously, Thr4 cannot be changed to Ala due to the fact that the side chain 
of Thr4 is needed to form the ester linkage.  2ClTrt-PS resin was used rather than the 
analogous TentaGel resin for most of these syntheses due to the much higher cost and lower 
loading of 2ClTrt-TG resin compared to 2ClTrt-PS resin.  In most cases the efficiency of 
the esterification reactions was greater than 90 % after two 13 h couplings when performed 
on 2ClTrt-PS resin (table 2.1).  The only exceptions were Dap-A1-E12-W13 which required 
only one 13 h coupling to attain 90 % efficiency, Dap-A3-E12-W13 which required three 
13 h couplings to attain 88 % efficiency and Dap-D-A2-E12-W13 which attained an 
efficiency of 81% after three 13 h couplings.  To determine if the high esterification 
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efficiency observed during the synthesis of the Dap-A6-E12-W13 analog on TentaGel resin 
mentioned earlier was transferable to other Dap analogs, Dap-A5-E12-W13 was prepared 
using the TentaGel resin. In this case, the esterification reaction was formed greater than 
95% efficiency after just one 13 h coupling in the absence of triton X-100.  
Table 2.1. Alanine analogs of Dap-E12-W13 prepared via a route analogous to that outlined 
in scheme 2.2. 
 
Dap analog 
 
Resin 
No. of 
Couplingsa 
 
0.1 %Triton 
Esterification 
Efficiency (%)b 
Dap-A1-E12-W13 2ClTrt-PS 1 yes 90 
Dap-D-A2-E12-W13 2ClTrt-PS 3 yes 81 
Dap-A3-E12-W13 2ClTrt-PS 3 yes 88 
Dap-A5-E12-W13 TentaGel 1 no >95 
Dap-A6-E12-W13 2ClTrt-PS 2 no 80 
Dap-A6-E12-W13 2ClTrt-PS 2 yes >95 
Dap-A6-E12-W13 TentaGel 2 no >95 
Dap-A6-E12-W13 TentaGel 2 yes >95 
Dap-L-A8-E12-W13 2ClTrt-PS 2 yes 95 
Dap-L-N9-E12-W13 Rink amide-PS 3 no 85 
Dap-A10-E12-W13 2ClTrt-PS 2 Yes 95 
Dap-D-A11-E12-W13 2ClTrt-PS 2 Yes 91 
Dap-A12-W13 2ClTrt-PS 2 Yes 92 
Dap-E12-A13 2ClTrt-PS 2 Yes >95 
aEsterification reactions were performed using 10 equiv FmocTrp(Boc)OH, 10 equiv 
DIPCDI, 0.1 eq. DMAP CH2Cl2, rt) either with or without 0.1 % triton X-100. FmocAlaOH 
was used instead of FmocTrp(Boc)OH for the synthesis of the Dap-E12-A13 analog. bThe 
percent efficiencies of the esterification reactions were determined by analytical RP-HPLC 
analysis of the released and deprotected peptides after the esterification reaction.87 
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2.3.2 In Vitro Antibacterial Activity of Dap-E12-W13 Analogs 
The in vitro antibacterial activity of Dap-E12-W13 and its alanine analogs was 
examined against B. subtilis 1046 at physiological Ca2+ concentration (1.25 mM) and 5 
mM Ca2+. The results are shown in table 2.2.  All of the alanine analogs exhibited higher 
MICs than Dap-E12-W13 at the lower Ca2+ concentration. Most of the analogs were 
more active at the higher Ca2+ concentration compared to the lower Ca2+ concentration.  
This observation is consistent with our previous studies (see chapter 1, section 1.4.2.3) 
where we found that Dap-E12-W13 and other analogs that are less active than Dap at 
physiological Ca2+ concentration, are usually more active at Ca2+ concentrations greater 
than physiological.67  
Only three residues, D-Asn2, Orn6 and Ser11, in Dap-E12-W13 appear to be 
amenable to substitution with Ala, without major loss of activity.  The A11 and A6 
analogs were only 1.5-fold less active than Dap-E12-W13 while the D-Ala2 analog was 
about 4-fold less active than Dap-E12-W13. The Ala1 and Ala3 analogs showed some 
activity at 5 mM Ca2+ but were still 30-fold less active than Dap-E12-W13.  The Ala13 
analog was 100-fold less active than Dap-E12-W13 at 5 mM Ca2+.  
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Table 2.2. In vitro antibacterial activity of Dap, Dap-E12-W13 
and alanine analogs of Dap-E12-W13 against B. subtilis 1046. 
 
Dap analog 
MIC (µg/mL) 
1.25 mM Ca2+ 5.0 mM Ca2+ 
Daptomycin 0.75 0.5 
Dap-E12-W13 3.5 1.0 
Dap-A1-E12-W13 >100 30 
Dap-D-A2-E12-W13 15 3 
Dap-A3-E12-W13 >100 30 
Dap-A5-E12-W13 35 4 
Dap-A6-E12-W13 5  0.5 
Dap-A7-E12-W13 >100a >100a 
Dap-L-A8-E12-W13 100 35 
Dap-L-N9-E12-W13 >100 35 
Dap-A10-E12-W13 >100 >100 
Dap-D-A11-E12-W13 5 0.5 
Dap-A12-W13 35 4 
Dap-E12-A13 >100 100 
aFrom reference 66 
 Our finding that Orn6 is amenable to substitution by Ala is consistent with previous 
reports that modifications can be made to Orn6 in Dap often without significant loss of 
activity.88 The finding that the D-Ala11 analog was also amenable to Ala substitution was 
expected as it had been previously shown that substitution of D-Ser11 in Dap with D-Ala, 
using the biosynthetic approach, had little effect on activity.59 Miao et al. have shown that 
substituting D-Asn2 with L-Asn2 resulted in a 10-fold reduction in activity suggesting that 
stereochemistry at this position is important to activity.88 Besides this substitution, no other 
residues have been examined at this position. Our results with the D-Ala2 analog suggest 
that this position is amenable to substitution so long as stereochemistry is maintained. 
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The finding that positions 2, 6 and 11 are amenable to substitution in Dap-E12-W13 
is consistent with the fact that these residues in Dap are not conserved in A54145 (figure 
2.2), a closely related Ca2+-dependent cLPA, which bears D-Asp, L-Ala and D-Gln at 
positions 2, 6 and 11 respectively, though stereochemistry is maintained at these positions.   
 
Figure 2.2.  Structure of A54145 
Our studies show that the Ala7, L-Ala8, Asn9 and Ala10 analogs of Dap-E12-W13 
were inactive or active at only the highest concentration tested (100 ug/mL at 1.25 mM 
Ca2+).  This is consistent with the results of Grunewald et al. who reported that replacing 
Asp7 and Asp9 with Asn in a Dap-L-N2-E12 analog resulted in complete loss of activity,58 
and supports the hypothesis that the D-X-D-G motif in Dap is crucial to its activity most 
likely because it is directly involved in binding Ca2+.   
Replacing Glu12 with Ala did not have a catastrophic effect on activity.  This suggests 
that Glu12 does not play a crucial role in determining activity and suggests that it does not 
have a major role in binding Ca2+. 
The L-Ala8 analog was significantly less active than Dap-E12-W13, which has D-
Ala at this position. Nguyen et al. reported that substitution of D-Ala8 in Dap with D-Lys 
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or D-Ser resulted in very little loss of activity.63 Moreover, these residues in A54145 are 
essentially reversed relative to Dap: L-Ala and D-Lys in A54145 are L-Orn6 and D-Ala8 in 
Dap. These results suggest that position 8 in Dap may also be amenable to variation so long 
as the correct stereochemistry is maintained.   
Our results also show that residues Trp13 (Kyn in Dap), Asp3, and Trp1 are also very 
important for biological activity, as the corresponding Ala analogs were inactive at the 
highest concentration tested.  Kyn13 in Dap has been substituted with Trp, Leu and Val and 
the resulting Trp13, Leu13 and Val13 analogs were 2- 4- and 8-fold less active than Dap, 
respectively.59 The Taylor group has substituted Kyn13 in Dap with Tyr and the resulting 
analog was 30-fold less active than Dap.67 Therefore, it appears that Dap can, to a certain 
degree, bear hydrophobic groups and certain aromatic residues at positions 1 and 13, but 
small residues, such as Ala, are not well tolerated.  
2.3.3 Membrane Binding Studies 
The interaction of Dap and Dap-E12-W13 with model membranes containing PG 
as a function of Ca2+ concentration can be monitored by following the increase in 
fluorescence and simultaneous blue shift of Kyn13 in Dap, or Trp1 and Trp13 in Dap-E12-
W13, as these residues insert into the a-polar environment of the membrane.39,85   
The intrinsic fluorescence of Dap (em = 400-600 nm) and Dap-E12-W13 (em = 
300-400 nm) in the presence of DMPC/DMPG (1:1) LUVs and DOPG/DOPC (1:1) LUVs 
as a function of Ca2+ concentration is shown in figure 2.3 (we will be referring to these 
types of plots as membrane binding curves (MBCs)).  With the DM LUVs, the fluorescence 
intensity of Dap does not increase significantly between 0-0.10 mM Ca2+. As the Ca2+ 
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concentration increases from 0.1-1.0 mM, the fluorescence intensity of Dap rapidly 
increases and then levels off above 1 mM. This is a typical MBC for Dap using 
DMPC/DMPG (1:1) LUVs.85 Dap-E12-W13 exhibits a similar binding curve, though it 
appears to respond to Ca2+ at slightly lower concentrations of Ca2+. A possible reason why 
the MBC for Dap is slightly different from the MBC for Dap-E12-W13 is because we are 
not following the fluorescence of the same residues in the two peptides: in Dap-E12-W13, 
the fluorescence intensity of both Trp1 and Trp13 is being monitored, while Kyn13 is being 
monitored with Dap. In either case, it has been suggested that it is the second step of Dap’s 
MOA that this increase in fluorescence above 0.05-0.1 mM Ca2+ is monitoring:  the binding 
of the second Ca2+, oligomer formation and deeper membrane insertion.89 
When DO LUVs are used, the MBCs are different from the MBCs obtained using 
DM LUVs.  With DO LUVs, both peptides appear to be very sensitive to Ca2+, as the 
fluorescence of both peptides increases rapidly between 0-0.1 mM Ca2+ and levels off above 
0.1 mM. So it appears that Dap and Dap-E12-W13 interact more avidly with LUVs 
composed of DO lipids than DM lipids.  This has been noted previously in the Taylor and 
Palmer groups for Dap.  The reason behind this is not known.   
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Figure 2.3. MBCs of Dap and Dap-E12-W13 in the presence of DMPC/DMPG (1:1) LUVs 
(on the left) and DOPG/DOPC (1:1) LUVs (on the right). 
  
MBCs were obtained for the Dap analogs listed in table 2.2 using DMPC/DMPG 
(1:1) and DOPC/DOPG (1:1) LUVs. The fluorescence of the Trp residues at position1 
and/or 13 was monitored. The MBCs for these analogs are given in Appendix B or are 
shown and discussed below. 
The fluorescence spectra for Dap-A6-E12-W13, which is only 1.5-fold less active 
than Dap-E12-W13 (table 2.2), in the presence of DM and DO LUVs at different Ca2+ 
concentrations and the associated MBCs are given in figure 2.4.  The MBCs of Dap-E12-
W13 are also shown.  The MBCs of Dap-A6-E12-W13 and Dap-E12-W13 with DM and 
DO LUVs are very similar which suggests that they have a similar affinity for Ca2+.   
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Figure 2.4. Fluorescence spectra of Dap-A6-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A6-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments. 
 
Another analog found to have antibacterial activity comparable to Dap-E12-W13 is 
Dap-A11-E12-W13.  The fluorescence spectra for Dap-A11-E12-W13 in the presence of 
DM and DO LUVs at different Ca2+ concentrations and the associated MBCs are given in 
figure 2.5.  The MBCs of Dap-E12-W13 are also shown. The MBCs of Dap-A11-E12-W13 
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and Dap-E12-W13 with DM and DO LUVs are very similar which suggests that they have 
a similar affinity for Ca2+.   
  
   
Figure 2.5. Fluorescence spectra of Dap-A11-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes, and increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A11-E12-W13 and Dap-E12-
W13 on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard 
deviation of three different experiments. 
 
The fluorescence spectra for Dap-A8-E12-W13, which is 35-fold less active than 
Dap-E12-W13 (table 2.2), in the presence of DM and DO LUVs at different Ca2+ 
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W13 are also shown.  The MBCs of Dap-A8-E12-W13 are very different from that of Dap-
E12-W13 in that it takes much higher concentrations of Ca2+ to achieve maximal binding 
of Dap-A8-E12-W13 to the LUVs compared to Dap-E12-W13.  This suggests that Dap-
A8-E12-W13 has a lower affinity for Ca2+ than Dap-E12-W13 and/or Ca2+-bound Dap-A8-
E12-W13 has a lower affinity for the LUVs than Ca2+-bound Dap-E12-W13.  The lower 
affinity of Dap-A8-E12-W13 for Ca2+ and/or the LUVs might be the reason for the reduced 
activity of this analog.   
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Figure 2.6. Fluorescence spectra of Dap-A8-E12-W13 in the presence of (A) 
DMPC:DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes, and increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D): MBCs of Dap-A8-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments.  
 
The Ca2+ concentration needed for Dap and Dap analogs obtained in this study to 
fully associate with DMPC/DMPG (1:1) and DOPC/DOPG (1:1) LUVs (as determined 
from the MBCs) and their MICs are given in table 2.3.  From the data in this table it can be 
seen that there is a correlation between MIC and the Ca2+ concentration required for Dap 
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and Dap analogs to fully associate with the LUVs: the higher the MIC the higher the 
concentration of Ca2+ required to achieve full membrane insertion.  These results suggest 
that a high affinity for Ca2+, whether at the first stage of Daps MOA (binding of the first 
Ca2+) or at the second stage of Daps MOA (binding of the second Ca2+, followed by deep 
membrane insertion), is required in order for the peptides to exhibit good biological activity.  
Table 2.3. Ca2+ concentration needed for Dap and Dap analogs to fully 
associate with DMPC/DMPG (1:1) and DOPC/DOPG (1:1) LUVs and the 
MICs of these analogs. 
 
 
 
Dap analog 
 
 
Ca2+ concentration needed for 
maximal membrane binding (mM) 
MICa 
(g/mL) 
DMPC/DMPG 
LUVs 
DOPC/DOPG 
LUVs 
Daptomycin 0.75 1 0.1 
Dap-E12-W13 3.5 1 0.1 
Dap-A1-E12-W13 >100 50 100 
Dap-D-A2-E12-W13 15 5 0.5 
Dap-A3-E12-W13 >100 50 50 
Dap-A5-E12-W13 35 10 10 
Dap-A6-E12-W13 5  1 0.1 
Dap-L-A8-E12-W13 100 50 50 
Dap-L-N9-E12-W13 >100 10 50 
Dap-A10-E12-W13 >100 50 50 
Dap-D-A11-E12-W13 5 0.5  0.5 
Dap-A12-W13 35 5 1 
Dap-E12-A13 >100 50 50 
 a1.25 mM Ca2+  
For those analogs whose MICs were ≥ 100 g/mL, high Ca2+ concentrations (50-
100 mM) were required for maximal membrane interaction regardless of the type of lipid 
(DM or DO).  However, the Dap-N9-E12-W13 analog was an exception. This analog was 
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inactive at 100 g/mL, but required only 10 mM Ca2+ to achieve maximal interactions with 
the DM liposomes (figure 2.7). Although it required 50 mM Ca2+ to achieve maximal 
interactions with the DO liposomes, it was more sensitive to Ca2+ with the DO liposomes 
than the other inactive analogs.  This analog appears to be capable of binding Ca2+ and 
inserting into the membrane relatively well. This suggests that Asp9 of the DXDG motif is 
not essential for Ca2+ binding and/or membrane insertion, yet is essential for activity and 
stoichiometry. Perhaps this analog can bind Ca2+, insert into the membrane but cannot form 
a functional oligomer.  ITC studies on this analog would be helpful in determining its Ca2+ 
affinity. Fluorescence studies, similar to those performed on Dap (see Chapter 1, section 
1.3), using Dap-N9-E12-W13 labelled with a fluorophore on the Orn residue, would be 
helpful in determining the extent of oligomer formation of this analog. 
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Figure 2.7. Fluorescence spectra of Dap-N9-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-N9-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of two different experiments. 
 
Like Dap and Dap-E12-W13, all of the analogs required lower Ca2+ concentrations 
to initiate interactions with the DO LUVs as compared to the DM LUVs. These results 
suggest that the greater sensitivity of these peptides to Ca2+ with the DO LUVs is due to an 
interaction between the decanoyl tail of the peptide and the lipids of the LUVs. 
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2.3.4 Dap-K6-X11-E12-W13 Analogs 
From the above Ala scan of Dap and from studies by Cubists Pharmaceuticals on 
Dap-X8 analogs (see chapter 1 section 1.4.2), it appears that four positions in Dap are 
amenable to substitution: positions 2, 6, 8, and 11.  As one of the ultimate objectives of this 
work is to obtain a Dap analog with improved activity against Dap-resistant bacteria and 
active in the presence of lung surfactant, we decided to begin making analogs of Dap 
starting with position 11. 
While the SAR studies presented in sections 2.3.1-3 were in progress, it was 
discovered by Robert Taylor, a graduate student in the Taylor and Palmer groups, that Dap-
K6-E12-W13 (see section 2.3.1) is almost as active as Dap at physiological Ca2+ 
concentration and was about 2.3-fold more active than Dap-E12-W13 at physiological Ca2+ 
concentration (table 2.4).  Therefore, it was decided to use Dap-K6-E12-W13 as the lead 
for the preparation of position 11 analogs.  
Table 2.4.  In vitro antibacterial activity of daptomycin, Dap-K6-E12-W13 and 
Dap-E12-W13 against B. subtilis 1046 and PY79. 
 MICs (ug/mL)a 
Strain Daptomycin Dap-K6-E12-W13 Dap-E12-W13 
B. subtilis 1046 0.75 (0.5) 1.5 (1.0) 3.5 (1.0) 
B. subtilis PY79 0.75 (0.75) 1.5 (0.75) 4.5 (3.0) 
aMICs presented outside brackets were obtained at 1.25 mM Ca2+.  MICs presented 
inside brackets were obtained at 5.0 mM Ca2+. 
 
 Seventeen amino acids, as their D-isomers, were substituted for D-Ser11 in Dap-
K6-E12-W13.  We did not prepare the Lys11 analog, as it had already been shown by 
researchers at Cubist that Dap can tolerate this residue at position 11 with little loss of 
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activity.59 The Ala11 analog was also not prepared, as we had already demonstrated above 
that Ala could be accommodated at position 11 in Dap-E12-W13. 
The analogs were prepared using the same approach as outlined in scheme 2.2 for 
Dap-E12-W13.  In brief, a large quantity of peptide 2.7 was prepared (scheme 2.3). This 
was achieved using automated Fmoc SPPS, with the exception of the formation of the depsi 
bond and the installation of Glu12, which were installed manually.  The resin was then 
sectioned into 17 smaller vessels, which were used to install the 17 D-amino acids at 
position 11 (peptides of type 2.8).  The resulting peptides were cyclized, deprotected, 
cleaved from the resin and purified by HPLC as previously described.  The HPLC 
chromatograms and mass spectra of these analogs are given in Appendix C. 
 
 
Scheme 2.3.  Synthesis of Dap-K6-X11-E12-W13 peptides. 
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 The in vitro antibacterial activity of the Dap-K6-X11-E12-W13 peptides were 
determined against B. subtilis 1046 at physiological Ca2+ concentration (1.25 mM) and 5 
mM Ca2+. The results are shown in table 2.5. None of the analogs were more active than 
Dap-K6-E12-W13; however, some interesting results were obtained.  
Table 2.5. In vitro antibacterial activity of Dap, Dap-K6-E12-W13, Dap-
A11-E12-W13, and Dap-K6-X11-E12-W13 against B. subtilis 1046. 
  
Dap analog 
MIC (ug/mL) 
Entry 1.25 mM Ca2+ 5.0 mM Ca2+ 
1 Daptomycin 0.75 0.5 
2 Dap-K6-E12-W13 1.5 0.5 
3 Dap-A11-E12-W13 5 0.5 
4 Dap-K6-D-H11-E12-W13 1.5 1 
5 Dap-K6-D-R11-E12-W13 2.5 0.5 
6 Dap-K6-D-N11-E12-W13 2.5 0.5 
7 Dap-K6-D-Q11-E12-W13 30 1.5 
8 Dap-K6-D-T11-E12-W13 4 0.85 
9 Dap-K6-D-C11-E12-W13 4 1.5 
10 Dap-K6-D-M11-E12-W13 4 0.5 
11 Dap-K6-G11-E12-W13 4 2.5 
12 Dap-K6-D-D11-E12-W13 30 7.5 
13 Dap-K6-D-E11-E12-W13 75 30 
14 Dap-K6-D-L11-E12-W13 30 1.5 
15 Dap-K6-D-V11-E12-W13 30 0.85 
16 Dap-K6-D-allo-I1e-E12-W13 30 4 
17 Dap-K6-D-F11-E12-W13 100 4 
18 Dap-K6-D-Y11-E12-W13 75 10 
19 Dap-K6-D-W11-E12-W13 >100 >100 
20 Dap-K6-D-P11-E12-W13 >100 30 
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Particularly surprising was the finding that the His11 analog (entry 4) was as active 
as Dap-K6-E12-W13 at physiological Ca2+ concentration. Moreover, the Arg11 analog 
(entry 5) was less than 2-fold less active than Dap-K6-E12-W13 at physiological Ca2+ 
concentration. Therefore, it appears that Dap can accommodate positively charged residues 
at position 11 very well.  Perhaps they are interacting with a phosphate group of a lipid in 
the membrane. In contrast, negatively charged residues at position 11 were quite 
detrimental to activity, with the Asp11 (entry 12) and Glu 11 (entry 13) analogs being 20- 
and 50-fold less active than the parent peptide, respectively.  In the case of the Asp11 
analog, the large loss of activity was due to the extra negative charge, as the Asn11 analog 
(entry 6) was almost as active as Dap-K6-E12-W13 at physiological Ca2+ concentration.  
However, this was not the case with the Gln11 analog, which was 20-fold less active than 
the parent peptide suggesting that the larger size (compared to Asp or Ser) and the negative 
charge contributed the reduced activity of the Glu analog. 
 Ser11 can be replaced with a Thr residue (entry 8) with only a 2.5-fold loss of 
activity, indicating that the addition of a methyl group to the side chain of Ser does not 
significantly affect activity. The Cys analog (entry 9) was also only 2.5-fold less active than 
the parent compound, indicating that the OH group of Ser11 can be replaced with an SH 
without causing a serious deleterious effect on activity. Moreover, the Met analog (entry 
10) was as active as the Cys analog.   
Gly11 (entry 11) was also only 2.5-fold less active than Dap-K6-E12-W13, 
indicating that a side chain at position 11 was not crucial to the antibacterial activity.   
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 Although an Ala residue can be accommodated at position 11, the incorporation of 
hydrophobic, branched residues (Leu (entry 14), Val (entry 15), and D-allo-Ile (entry 16)), 
was detrimental to activity.  The incorporation of uncharged aromatic residues (Phe (entry 
17), Tyr (entry 18), and Trp (entry 19)) at position 11 resulted in a large decrease in activity.  
The Pro analog (entry 20) was one of the least active, showing no activity at 100 
g/mL. This is probably due to the proline causing a significant change in the overall 3-D 
structure of the peptide which probably significantly affected the ability of the analog to 
bind Ca2+.   
  
61 
 
Chapter 3 
Summary and Future Work 
3.1 Summary 
Daps unresolved MOA, the increasing appearance of Dap resistant bacteria, and the 
inability of Dap to treat community-acquired pneumonia stresses the need for the 
development and study of new Dap analogs. To begin addressing these issues, an SAR 
study, in the form of an alanine scan, was performed on Dap-E12-W13, a relatively active 
and synthetically accessible analog of Dap.  This was done to determine which amino acids 
can be substituted with alanine without significantly adversely affecting Dap’s biological 
activity and which amino acids are important for Dap’s ability to interact with membranes. 
The analogs were prepared using a solid phase approach, which requires only Fmoc 
building blocks, recently developed in the Taylor group.  It was found that the formation of 
the ester bond and the on-resin cyclization was more readily achieved when the peptides 
were prepared using Tenta-gel resin as opposed to standard polystyrene resin.  The 
antibacterial activities of the peptides revealed that positions 2, 6, and 11 were amenable to 
substitution.  It is also likely, based on the work of Cubist Pharmaceuticals, that position 8 
is also amenable to substitution so long as the correct stereochemistry is maintained. 
Membrane binding studies with the Ala analogs revealed that the ability of the analogs to 
act as an antibiotic was closely related to their ability to bind calcium and interact with 
membranes.   
Since the Ala scan revealed that position 11 was amenable to substitution, we 
prepared analogs of Dap-K6-E12-W13, an analog with activity approaching that of Dap, in 
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which Ser 11 was replaced with 17 of the common 20 amino acids.  Although none of these 
analogs were more active than the parent peptide, these studies revealed that position 11 
was particularly amenable to substitution with positively charged amino acids (His, Arg, 
Lys) as these substitutions resulted in either no or minimal loss of activity.  Moreover, the 
Asn, Thr, Cys, Met and Gly analogs were also relatively active being only 2.7-fold less 
active than Dap-K6-E12-W13.   
3.2 Future Work  
Membrane permeabilization studies, as mentioned in Chapter 1, section 1.3, will be 
conducted on selected analogs derived from the Ala scan to determine how the substitution 
affects membrane permeabilization. Membrane binding curves will be obtained for the 
position 11 analogs of Dap-K6-E12-W13 to determine if these substitutions affect calcium 
affinity and membrane binding.  These studies will be followed up with membrane 
permeabilization studies on selected analogs.  We will also determine the biological activity 
of these analogs in the presence of synthetic lung surfactant and with Dap-resistant bacteria. 
More Dap analogs will be prepared and their antimicrobial activity, in the presence 
and absence of lung surfactant, as well as their ability to interact with and permeabilize 
membranes, will be determined. For these studies, we will be substituting positions 2, 6 and 
8 in Dap-K6-E12-W13 with the other common acids.   
As mentioned in Chapter 1, section 1.3, Dap derivatives bearing fluorescent tags on 
the Orn residue and lipid tail have proven to be very useful as tools for studying Dap’s 
MOA.  It would be helpful for MOA studies if a fluorophore could be attached to another 
position in Dap. Unfortunately, in native Dap, the Orn residue and the lipid tail are the only 
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two places that a fluorescent tag can be easily attached.  However, in this thesis, we have 
shown that the Dap-K6-C11-E12-W13 analog was quite active.  Since it is relatively easy 
to append fluorescent dyes to Cys residues, we will append fluorescent tags to Dap-K6-
C11-E12-W13.  If such derivatives are biologically active, then it should be possible to use 
these fluorescent peptides to further study Dap’s MOA.  
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Appendix A 
HPLC Chromatograms and ESI+ Mass spectra of Dap Alanine Analogs  
 
Analytical HPLC gradient: 90% Acetonitrile and 10% H2O (0.1% TFA) to 10% Acetonitrile and 
90% H2O (0.1% TFA) in over 50 min. 
 
 
  
Figure A.1 (A) Analytical HPLC chromatogram of purified Dap-A1-E12-W13. (B) HRMS 
of purified Dap-A1-E12-W13, peak at m/z = 1488.66772 corresponds to [M+H]2+ and m/z 
= 744.33600 corresponds to [M+2H]2+. 
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Figure A.2.  (A) Analytical HPLC chromatogram of purified Dap-A2-E12-W13. (B) HRMS 
of purified Dap-A2-E12-W13, peak at m/z = 1560.7043 corresponds to [M+H]2+ and m/z = 
780.35425 corresponds to [M+2H]2+. 
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Figure A.3.  (A) Analytical HPLC chromatogram of purified Dap-A3-E12-W13. (B) HRMS 
of purified Dap-A3-E12-W13, peak at m/z = 1558.71765 corresponds to [M+H]2+ and m/z 
= 779.86206 corresponds to [M+2H]2+. 
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Figure A.4.  (A) Analytical HPLC chromatogram of purified Dap-A5-E12-W13. (B) HRMS 
of purified Dap-A5-E12-W13, peak at m/z = 1617.72595 corresponds to [M+H]2+ and m/z 
= 808.86499 corresponds to [M+2H]2+. 
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Figure A.5.  (A) Analytical HPLC chromatogram of purified Dap-A6-E12-W13. (B) HRMS 
of purified Dap-A6-E12-W13, peak at m/z = 1560.66736 corresponds to [M+H]2+ and m/z 
= 1560.66736 corresponds to [M+2H]2+. 
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Figure A.6.  (A) Analytical HPLC chromatogram of purified Dap-A8-E12-W13. (B) HRMS 
of purified Dap-A8-E12-W13, peak at m/z = 1603.709 corresponds to [M+H]2+ and m/z = 
801.85693 corresponds to [M+2H]2+. 
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Figure A.7.  (A) Analytical HPLC chromatogram of purified Dap–N9-E12-W13. (B) HRMS 
of purified Dap-N9-E12-W13, peak at m/z = 1601.91096 corresponds to [M+H]2+ and m/z 
= 801.50752 corresponds to [M+2H]2+. 
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Figure A.8. (A) Analytical HPLC chromatogram of purified Dap -A10-E12-W13. (B) 
HRMS of purified Dap-A10-E12-W13, peak at m/z = 1617.72 corresponds to [M+H]2+ and 
m/z = 808.86487 corresponds to [M+2H]2+. 
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Figure A.9.  (A) Analytical HPLC chromatogram of purified Dap -A11-E12-W13. (B) 
HRMS of purified Dap-A11-E12-W13, peak at m/z = 1587.713 corresponds to [M+H]2+ 
and m/z = 793.85950 corresponds to [M+2H]2+. 
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Figure A.10.  (A) Analytical HPLC chromatogram of purified Dap-A12-W13. (B) HRMS 
of purified Dap-A12-W13, peak at m/z = 1545.7054 corresponds to [M+H]2+ and m/z = 
772.85425 corresponds to [M+2H]2+. 
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Figure A.11.  (A) Analytical HPLC chromatogram of purified Dap-A13-E12. (B) HRMS of 
purified Dap-A13-E12, peak at m/z = 1488.66821 corresponds to [M+H]2+ and m/z = 
744.33600 corresponds to [M+2H]2+. 
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Appendix B 
Membrane Binding Curves of Dap Alanine Analogs 
 
  
  
 
Figure B.1 Fluorescence spectra of Dap-A1-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A1-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments. 
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Figure B.2. Fluorescence spectra of Dap-A2-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A2-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments. 
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Figure B.3. Fluorescence spectra of Dap-A3-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A3-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments. 
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Figure B.4. Fluorescence spectra of Dap-A5-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A5-E12-W13 and Dap-E12-W13 
on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard deviation 
of three different experiments. 
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Figure B.5. Fluorescence spectra of Dap-A10-E12-W13 in the presence of (A) 
DMPC/DMPG (1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ 
concentration (mM) at 37 °C. (C) and (D):  MBCs of Dap-A10-E12-W13 and Dap-E12-
W13 on DMPC/DMPC and DOPC/DOPG liposomes. Error bars represent the standard 
deviation of three different experiments. 
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Figure B.6. Fluorescence spectra of Dap-A12-W13 in the presence of (A) DMPC/DMPG 
(1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ concentration 
(mM) at 37 °C. (C) and (D):  MBCs of Dap-A12-W13 and Dap-E12-W13 on DMPC/DMPC 
and DOPC/DOPG liposomes. Error bars represent the standard deviation of three different 
experiments. 
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Figure B.7. Fluorescence spectra of Da-E12-A13 in the presence of (A) DMPC/DMPG 
(1:1) liposomes, (B) DOPC/DOPG (1:1) liposomes with increasing Ca2+ concentration 
(mM) at 37 °C. (C) and (D):  MBCs of Dap-E12-A13 and Dap-E12-W13 on DMPC/DMPC 
and DOPC/DOPG liposomes. Error bars represent the standard deviation of three different 
experiments. 
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Appendix C 
HPLC Figures and ESI+-MS of Dap-K6-X11-E12-W13 Analogs 
 
 
Analytical HPLC gradient: 90% Acetonitrile and 10% H2O (0.1% TFA) to 10% Acetonitrile and 
90% H2O (0.1% TFA) in over 50 min. 
 
 
 
A 
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Figure C.1.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-H11-E12-W13. 
(B) HRMS of purified Dap-K6-D-H11-E12-W13, peak at m/z = 1666.58 corresponds to 
[M+H]2+ and m/z = 834.92 corresponds to [M+2H]2+. 
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Figure C.2.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-R11-E12-W13. 
(B) HRMS of purified Dap-K6-D-R11-E12-W13, peak at m/z = 1686.83 corresponds to 
[M+H]2+ and m/z = 844.00 corresponds to [M+2H]2+. 
 
 
 
Figure C.3.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-N11-E12-W13. 
(B) HRMS of purified Dap-K6-D-N11-E12-W13, peak at m/z = 1644.67 corresponds to 
[M+H]2+ and m/z = 822.42 corresponds to [M+2H]2+. 
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Figure C.4.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-Q11-E12-W13. 
(B) HRMS of purified Dap-K6-D-Q11-E12-W13, peak at m/z = 1658.67 corresponds to 
[M+H]2+ and m/z = 829.42 corresponds to [M+2H]2+. 
 
  
A 
B 
96 
 
 
 
 
Figure C.5.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-T11-E12-W13. 
(B) HRMS of purified Dap-K6-D-T11-E12-W13, peak at m/z = 1631.83 corresponds to 
[M+H]2+ and m/z = 816.50 corresponds to [M+2H]2+. 
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Figure C.6.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-C11-E12-W13. 
(B) HRMS of purified Dap-K6-D-C11-E12-W13, peak at m/z = 1632.67 corresponds to 
[M+H]2+ and m/z = 817.33 corresponds to [M+2H]2+. 
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Figure C.7.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-M11-E12-W13. 
(B) HRMS of purified Dap-K6-D-M11-E12-W13, peak at m/z = 1661.58 corresponds to 
[M+H]2+ and m/z = 831.83 corresponds to [M+2H]2+. 
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Figure C.8.  (A) Analytical HPLC chromatogram of purified Dap-K6 -G11-E12-W13. (B) 
HRMS of purified Dap-K6-G11-E12-W13, peak at m/z = 1586.58 corresponds to [M+H]2+ 
and m/z = 794.83 corresponds to [M+2H]2+. 
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Figure C.9.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-D11-E12-W13. 
(B) HRMS of purified Dap-K6-D-D11-E12-W13, peak at m/z = 1644.58 corresponds to 
[M+H]2+ and m/z = 823.66 corresponds to [M+2H]2+. 
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Figure C.10.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-E11-E12-W13. 
(B) HRMS of purified Dap-K6-D-E11-E12-W13, peak at m/z = 1659.67 corresponds to 
[M+H]2+ and m/z = 830.92 corresponds to [M+2H]2+. 
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Figure C.11.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-L11-E12-W13. 
(B) HRMS of purified Dap-K6-D-L11-E12-W13, peak at m/z = 1643.67 corresponds to 
[M+H]2+ and m/z = 822.92 corresponds to [M+2H]2+. 
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Figure C.12.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-V11-E12-W13. 
(B) HRMS of purified Dap-K6-D-V11-E12-W13, peak at m/z = 1629.67 corresponds to 
[M+H]2+ and m/z = 815.95 corresponds to [M+2H]2+.    
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Figure C.13.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-allo-Ile11-E12-
W13. (B) HRMS of purified Dap-K6-D-allo-Ile11-E12-W13, peak at m/z = 1643.75 
corresponds to [M+H]2+ and m/z = 822.93 corresponds to [M+2H]2+. 
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Figure C.14.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-F11-E12-W13. 
(B) HRMS of purified Dap-K6-D-F11-E12-W13, peak at m/z = 1676.67 corresponds to 
[M+H]2+ and m/z = 839.92 corresponds to [M+2H]2+. 
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Figure C.15.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-Y11-E12-W13. 
(B) HRMS of purified Dap-K6-D-Y11-E12-W13, peak at m/z = 1692.75 corresponds to 
[M+H]2+ and m/z = 847.42 corresponds to [M+2H]2+. 
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Figure C.16.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-W11-E12-W13. 
(B) HRMS of purified Dap-K6-D-W11-E12-W13, peak at m/z = 1715.67 corresponds to 
[M+H]2+ and m/z = 858.83 corresponds to [M+2H]2+. 
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Figure C.17.  (A) Analytical HPLC chromatogram of purified Dap-K6-D-P11-E12-W13. 
(B) HRMS of purified Dap-K6-D-P11-E12-W13, peak at m/z = 1626.67 corresponds to 
[M+H]2+ and m/z = 814.83 corresponds to [M+2H]2+. 
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